nefazodone has been researched along with Sexual Dysfunction, Physiological in 3 studies
nefazodone: may be useful as an opiate adjunct
Sexual Dysfunction, Physiological: Physiological disturbances in normal sexual performance in either the male or the female.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anecdotal reports have suggested that the long-term use of selective serotonin reuptake inhibitors (SSRIs) may be associated with significant weight gain, sexual dysfunction, drug interactions, and discontinuation symptoms." | 2.41 | Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. ( Gupta, S; Masand, PS, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moll, JL | 1 |
| Brown, CS | 1 |
| Masand, PS | 1 |
| Gupta, S | 1 |
| Waldinger, MD | 1 |
| Zwinderman, AH | 1 |
| Olivier, B | 1 |
| Schweitzer, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1-b Non-blinded Study of Safety, Tolerability and Efficacy of Lorexys in Premenopausal Women With Hypoactive Sexual Desire Disorder[NCT01857596] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| The Effects of a High Eicosapentaenoic Acid Multinutrient Supplement on Measures of Stress, Anxiety and Depression in Young Adults: a Randomised, Double-blind, Placebo-controlled Trial.[NCT04844034] | 94 participants (Anticipated) | Interventional | 2022-04-19 | Recruiting | |||
| Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause[NCT03740009] | Phase 4 | 20 participants (Actual) | Interventional | 2019-01-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary outcome measure is functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. All participants will complete the fMRI Monetary Incentive Delay (MID) task at baseline and at 3 weeks. During the task, participants need to select the correct response during win and lose conditions by pressing a button on a button box in the MRI. Participant's blood-oxygen-level dependent (BOLD) activation response (A measurement of oxygen level that is released to neurons since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen to perform the tasks.) is measured while they performed the task in MRI scanner." (NCT03740009)
Timeframe: Baseline to 3 weeks
| Intervention | percent signal change (Mean) | |||||
|---|---|---|---|---|---|---|
| Caudate Baseline | Caudate Posttreatment | Nucleus Accumbens Baseline | Nucleus Accumbens Posttreatment | Putamen Baseline | Putamen Posttreatment | |
| Perimenopausal Women, Depressed | .0704 | .0475 | .0623 | .0280 | .0399 | .0408 |
The second primary outcome measure uses the Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Scale (MASQ-AD) to examine symptom change. All participants will complete the MASQ-AD at each study visit, which measures their current symptoms of depression and anxiety. Scores range from 22 to 110 with lower scores reflecting a better outcome. (NCT03740009)
Timeframe: Baseline, week 2, week 3, week 4 (post treatment)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline Week 1 | Week 2 | Week 3 | Post Treatment Week 4 | |
| Perimenopausal Women, Depressed | 72.1 | 62.4 | 57.2 | 54.5 |
2 reviews available for nefazodone and Sexual Dysfunction, Physiological
| Article | Year |
|---|---|
The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature.
Topics: Antidepressive Agents, Second-Generation; Apomorphine; Biogenic Monoamines; Central Nervous System S | 2011 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
1 other study available for nefazodone and Sexual Dysfunction, Physiological
| Article | Year |
|---|---|
Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy.
Topics: Antidepressive Agents; Coitus; Data Interpretation, Statistical; Ejaculation; Fluoxetine; Fluvoxamin | 2008 |